White House Strikes Drug Pricing Deal with Regeneron Pharmaceuticals
The White House is set to announce a drug pricing agreement with Regeneron Pharmaceuticals, the only major drugmaker among 17 contacted by President Trump in July, to finalize such a deal. The announcement has already resulted in a more than 2% rise in Regeneron's stock value during morning trading.
The White House is gearing up to unveil a significant drug pricing agreement with Regeneron Pharmaceuticals this Thursday, as disclosed by a source aware of the development.
Out of the 17 major pharmaceutical companies that President Donald Trump appealed to in July with proposals for such agreements, Regeneron Pharmaceuticals stands as the sole company to advance towards an accord at this time. Reuters was unable to receive an immediate comment from Regeneron regarding the announcement.
Anticipation of the deal has already had a positive impact on Regeneron's market performance, with the company's shares rising over 2% in morning trading.
ALSO READ
-
Regeneron Strikes Historic Drug Pricing Deal with White House
-
White House Accuses China of Massive AI IP Theft Ahead of Crucial Summit
-
White House Accuses China of AI Intellectual Property Theft
-
Trump Administration's Controversial White House Ballroom Project
-
White House's Secret Bunker: The Ballroom Controversy
Google News